Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”

The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”

“…Tae et al [ 4 ] made the meaningful observation in their letter that only 3 Asian studies have addressed this issue, and in fact, this meta-analysis had no choice but to analyze differences between clinical practice in the West (0.4 mg) and the East (0.2 mg). However, most of the previous Asian studies—in particular, benign prostatic hyperplasia guidelines in Korea and Japan— have proven the efficacy of TAM 0.2 mg as the initial dose.…”

“…2 of our study [ 1 ] is recommended. Moreover, as indicated in the letter [ 4 ], it is difficult to argue for the overall efficacy and safety of TAM because there was no assessment of adverse events. Finally, as was well explained in the letter [ 4 ], more research by researchers in the field is required to confirm the appropriate dose of TAM.…”